Prevention & lipidsCase-control study
Immunological risk identified by single-cell multi-omics and cardiovascular outcomes
- Nested case-control study
- exploratory proof-of-concept
- single-centre cohort
- validated in two independent cohorts
Authors' conclusion
Multi-omic profiling of blood immune cells revealed novel immune signatures associated with CAD, short- and long-term cardiovascular disease outcomes that are independent of systemic inflammation and may be used as risk stratification tools in the future.
Study context
- Population
- Patients from the LURIC cohort with and without angiographically confirmed coronary artery disease (CAD)nested in LURIC (n = 3316)
- Participants
- Forty-four patients
- Comparison
- Patients with vs without angiographically confirmed CAD and defined survival status
Main finding
As reported in the abstract
Immune signatures by multi-omics in blood immune cells
- Immunological signals not detectable with conventional biomarkers, incl. prominent T-cell proliferation signature linked to activation, memory formation, clonal expansion, interferon signalling and cytokine secretion
- Cell types and transcriptional programmes associated with CAD status and poor long-term survival
- Associations independent of high-sensitivity C-reactive protein (hsCRP) and IL-6 (originating from myeloid cells)
- exploratory proof-of-concept
Observational data: associations, not effects.
Further findings
Replication in independent cohorts
- Key findings replicated using single-cell RNA (scRNA) sequencing datasets
- 136
- Cellular proliferation confirmed by protein validation in atherosclerotic plaques
- Signatures evaluated as stratification tools to predict short-term outcomes in ACS
Original publication
Immunological risk identified by single-cell multi-omics and cardiovascular outcomes. Eur Heart J. Published 14 August 2026. doi:10.1093/eurheartj/ehag553
Summarised from the published abstract; every number is checked against it